IL17A and rheumatoid arthritis: However, based on the role played by the immune system in RA, novel therapeutic regimens are also used and include propagation of Tregs, use of biologic DMARDs targeting IL-17, IL-6, and granulocyte-macrophage colony-stimulating factor, TNF inhibitors, anti-CD20, and immunoproteasome inhibitors [8].